https://biospectrumindia.com/rssfeed/states/punjab punjab https://biospectrumindia.com/news/111/28435/vice-president-inaugurates-advanced-instrumentation-facility-at-panjab-university.html https://biospectrumindia.com/news/111/28435/vice-president-inaugurates-advanced-instrumentation-facility-at-panjab-university.html Sat, 05 Sep 2026 13:37:57 +0530 The Vice President of India and ex-officio Chancellor of Panjab University, C.P. Radhakrishnan, recently visited Panjab University, Chandigarh. During his visit, the Vice President inaugurated the Advanced Instrumentation Facility at the Sophisticated Analytical Instrument Facility/Central Instrumentation Laboratories (SAIF/CIL). He also inaugurated the Panjab University Tech Innovation Forum (PU-TIF). SAIF/CIL and PU-TIF are important components of the University's academic, applied, and translational research ecosystem, providing advanced analytical, incubation, and entrepreneurial support to researchers, innovators, and industry. C.P. Radhakrishnan said that the installation of five advanced scientific instruments – Atomic Force Microscope, Raman Spectrometer, DNA Sequencer, Flow Cytometer and FTIR Spectrometer – will significantly strengthen the research capabilities of the University in various fields including nanotechnology, materials science, environmental science and genomics. Highlighting the importance of innovation, the Vice President said that Bio-Nest's transformation from a Section 8 non-profit company into the Panjab University Tech Innovation Forum represents a new institutional framework to advance research , entrepreneurship , and technology development. He emphasised that innovation flourishes when academia, industry, incubators, and investors work together. ]]> https://biospectrumindia.com/news/111/28377/kedaara-capital-announces-200-m-strategic-investment-in-tynor-orthotics.html https://biospectrumindia.com/news/111/28377/kedaara-capital-announces-200-m-strategic-investment-in-tynor-orthotics.html Tue, 25 Aug 2026 21:24:10 +0530 Kedaara Capital has announced a strategic investment of $200 million in Mohali-based Tynor Orthotics Private Limited. Founded in 1993, Tynor has grown into India’s #1 doctor recommended brand in orthopaedic supports, mobility aids, rehabilitation and sports performance enhancement solutions with an extensive reach spanning over 300,000 retail outlets and 8,000 hospitals across 60 countries. Tynor's products have supported more than 100 million lives making healthcare affordable and accessible. It also operates three state-of-the-art facilities across 6.5 lac sq. ft. with its best-in-class lean manufacturing capabilities to deliver global-grade products at competitive prices. Kedaara will work closely with the promoters, Dr P.J. Singh and A.J. Singh, the professional management team and long-standing strategic partner Thuasne® to build a leading ortho-focused wellness platform — deepening the brand's reach across India, expanding its presence in international markets, and continuing to invest in world-class, efficient manufacturing, as the company enters its next phase of growth. Sunish Sharma, Founder and Managing Partner, Kedaara Capital, said, "India's medical devices sector is among the fastest-growing in the world, and Tynor represents a rare opportunity to partner with a clear category leader in orthopaedic supports and rehabilitation."  Sumit Gupta, Managing Director, and Nishant Naveen, Principal, Co-Leads Healthcare and Pharma, Kedaara Capital, said, "We are excited to partner with the exceptional team of Tynor and see significant headroom to further build on Tynor's strong doctor equity, deep distribution, R&D capabilities, strong systems and lean manufacturing foundation. We look forward to closely working alongside the promoters, management team, and Thuasne®, and leveraging Kedaara’s operating expertise to help scale Tynor into a global orthotics champion." ]]> https://biospectrumindia.com/news/111/28299/dr-jitendra-kumar-former-md-birac-joins-iiser-mohali-as-professor-of-practice.html https://biospectrumindia.com/news/111/28299/dr-jitendra-kumar-former-md-birac-joins-iiser-mohali-as-professor-of-practice.html Wed, 12 Aug 2026 18:11:53 +0530 The Indian Institute of Science Education and Research (IISER) Mohali has announced the appointment of Prof. (Dr) Jitendra Kumar as Professor of Practice, effective from August 3, 2026. Dr Kumar is a distinguished biotechnology leader with more than two decades of experience in research, innovation, technology commercialization, entrepreneurship, and science policy. Before joining IISER Mohali, he served as the Managing Director (MD) of the Biotechnology Industry Research Assistance Council (BIRAC) under the Department of Biotechnology, Government of India, where he played a pivotal role in strengthening India's biotechnology innovation ecosystem. During his tenure, he led initiatives focused on policy formulation, technology commercialisation, funding mechanisms, and mentoring biotechnology start-ups, significantly contributing to the growth of the country's innovation landscape. Previous to joining BIRAC he has served as the Managing Director of Bangalore Bioinnovation Centre, a joint initiative of the Department of Biotechnology Government of India and Department of IT, BT and S&T, Government of Karnataka, where he was involved in building a vibrant Biotech Innovation and start up ecosystem.   Dr Kumar earned his Ph.D. in Biotechnology from the Institute of Microbial Technology (IMTECH), Chandigarh, affiliated with Jawaharlal Nehru University. He subsequently pursued postdoctoral research at the University of Illinois at Chicago and The Ohio State University, USA. In addition, he holds an MBA in Technology Entrepreneurship and Commercialization from The Ohio State University, reflecting his strong academic foundation in both science and innovation management. He moved to India in 2009 as Vice President of IKP Knowledge Park, Hyderabad, where he contributed significantly to the evolving landscape of startups and Innovation ecosystem. Over the course of his distinguished career, Dr Kumar has made substantial contributions to biotechnology innovation, translational research, technology management, incubation, and entrepreneurship. He has been instrumental in establishing innovation ecosystems, mentoring numerous biotechnology start-ups, formulating national and state-level biotechnology and start-up policies, and leading several high-impact research and innovation programmes. His contributions are reflected in an impressive portfolio of scientific publications, patents, policy initiatives, and numerous national and international recognitions. As Professor of Practice, Dr Kumar will work closely with faculty members, researchers, students, and innovators to promote interdisciplinary research, foster innovation and entrepreneurship, strengthen industry-academia collaborations, and facilitate the translation of scientific discoveries into societal and industrial impact. His appointment is expected to further enhance IISER Mohali's efforts in advancing translational research, technology development, and innovation-driven education. ]]> https://biospectrumindia.com/news/111/28190/rj-corp-healthcare-launches-cocoon-hospital-in-chandigarh.html https://biospectrumindia.com/news/111/28190/rj-corp-healthcare-launches-cocoon-hospital-in-chandigarh.html Fri, 24 Jul 2026 14:25:46 +0530 RJ Corp Healthcare has announced the launch of Cocoon Hospital, Chandigarh, a premium mother and child healthcare facility dedicated to delivering integrated, technology-enabled and compassionate care for women, mothers, newborns and children. The launch comes at a significant time for Chandigarh's healthcare landscape, as the city continues to emerge as a major hub for advanced medical services through both public and private sector investments. Cocoon Hospitals complement this evolving ecosystem by bringing specialised maternal and child healthcare closer to families across the region. Guided by its philosophy of "Creating Lifelong Bonds," Cocoon Hospitals has been envisioned as a comprehensive destination where every stage of parenthood—from pregnancy planning and antenatal care to high-risk pregnancies, childbirth, neonatal intensive care, paediatrics and women's wellness—is supported through evidence-based clinical expertise and compassionate care. Sharing his thoughts on the expansion, Ravi Kant Jaipuria, Founder & Chairman, RJ Corp Healthcare, said: "Our expansion strategy is well underway, with upcoming advanced facilities in Lucknow and Guwahati, as we continue building a nationwide network of specialised maternal and child healthcare ecosystems." Designed to meet the evolving needs of modern families, Cocoon Hospitals offer comprehensive services across obstetrics, gynaecology, fertility, foetal medicine, neonatal intensive care, paediatrics and women's health. The launch of Cocoon Hospital, Chandigarh, further reinforces RJ Corp Healthcare's long-term vision of expanding specialised maternal and child healthcare across India. Alongside the upcoming pipeline projects in Lucknow and Guwahati, this network expansion is poised to set new benchmarks in pregnancy care, neonatal medicine and paediatric healthcare for families across Chandigarh, Punjab, Haryana, Himachal Pradesh and the wider North India region.   ]]> https://biospectrumindia.com/news/111/28147/modi-launches-new-healthcare-initiatives-at-pgimer-chandigarh.html https://biospectrumindia.com/news/111/28147/modi-launches-new-healthcare-initiatives-at-pgimer-chandigarh.html Sat, 18 Jul 2026 12:49:10 +0530 Prime Minister Narendra Modi inaugurated the state-of-the-art Maternal and Child Centre and Centre for Advanced Neurosciences at the Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh. On this occasion, he also laid the foundation stone of a 150 bedded state-of-the-art Critical Care Block at PGIMER, Chandigarh under the Pradhan Mantri Ayushman Bharat Health Infrastructure Mission (PM-ABHIM). Minister said that the inauguration of state-of-the-art healthcare facilities and the foundation stone of new projects at PGIMER is an important step towards providing quality healthcare services to lakhs of people. Highlighting the importance of the new healthcare facilities being dedicated to the nation, Jagat Prakash Nadda, Union Minister of Health and Family Welfare, said that the 300 bedded state-of-the-art Neurology Centre is a landmark achievement in the field of neurological healthcare in India. He informed that for almost five decades from 1967, only 25 beds were available for Neurology and Neurosurgery in PGIMER, whereas this new centre will give a transformational boost to the healthcare capacity of the institute. Built at a cost of about Rs 440 crore, the Centre will provide a one-stop solution for neurology, neurosurgery and neurocritical care, making it more accessible to people to access state-of-the-art neurological treatments.  Nadda said that the state-of-the-art Mother and Child Centre is one of the most modern healthcare facilities available for women and children in the country, providing comprehensive and specialist medical services at one place. Equipped with 300 beds and state-of-the-art medical facilities, the centre will significantly strengthen maternal and child health services and benefit thousands of families in the region. ]]> https://biospectrumindia.com/news/111/27881/inst-develops-light-powered-nanocatalyst-as-cost-effective-way-to-manufacture-drugs-and-chemicals.html https://biospectrumindia.com/news/111/27881/inst-develops-light-powered-nanocatalyst-as-cost-effective-way-to-manufacture-drugs-and-chemicals.html Fri, 29 May 2026 22:22:03 +0530 A team of scientists from the Mohali-based Institute of Nano Science and Technology (INST) of the Department of Science and Technology (DST) has developed an innovative light-powered nano-catalyst to eliminate toxic solvents, high-temperature and energy-intensive processes in the manufacture of pharmaceuticals and industrial chemicals. This makes these processes cleaner and far more energy efficient. Globally, there is a need to reduce pollution, energy consumption, and the use of toxic chemicals in industrial processes. The nanomaterial has been designed and synthesised from a combination of gold, BODPI and palladium. It functions with the ability to absorb light energy by gold nanoparticles, which are again transferred to the BODPI molecule and finally to the active catalyst palladium. Palladium uses this transferred energy to conduct chemical reactions more efficiently, reducing energy consumption throughout the process. Combining three different components – gold, BODIPI, and palladium – into a single system helps in a more powerful and sustainable catalytic process. This technology can enable cleaner and more cost-effective production of drugs and chemicals, reducing environmental pollution and energy consumption. ]]> https://biospectrumindia.com/news/111/27629/leeford-builds-science-led-skincare-presence-with-alite.html https://biospectrumindia.com/news/111/27629/leeford-builds-science-led-skincare-presence-with-alite.html Wed, 08 Apr 2026 00:00:00 +0530 Punjab-based Leeford Healthcare is targeting the fast-growing health and personal care segment with its science-based skincare line of products with it’s Alite brand of skincare, as it looks to cater to a growing need in India for affordable, ingredient-based acne care solutions. India’s skincare market is on the rise and the anti-acne category is a key driver of it. Estimates for India’s anti-acne market size of ~ $350 million in 2024 are based on increasing awareness, acne incidence for younger people, and science-based products. Amit Gupta - Founder & Managing Director - Leeford Healthcare, said “Our experience with 75+ therapeutic segments has shown that outcomes are closely linked to consistency. In skincare, we saw an opportunity to bring a similar approach—creating solutions that consumers can use comfortably over time, rather than short-term fixes.” A trend in the skincare industry is that ingredients are being recognised and consumers are looking at formulation transparency and performance. Alite’s formulations are composed of Niacinamide PC, which is known for skin repair and tolerance, DSBC (Silanediol Salicylate), which is a new derivative to treat acne “& repair acneic skin” with hydration.  These ingredients represent the transition from one to multi-purpose to next-generation formulations that can also improve skin compatibility, which is still underpenetrated in the mid-priced range. Skincare is part of Leeford’s larger strategy to build a diversified consumer healthcare portfolio. With a presence across 75+ therapeutic segments & distribution network of over 1 million retail touchpoints, the company is well-positioned to scale consumer brands, particularly in Tier 2 and Tier 3 markets, where demand for affordable and quality skincare is growing rapidly.  According to industry data, over 60% of skincare consumption growth is now coming from non-metro markets, so distribution strength is a key competitive advantage. The company is expanding Alite's presence in General trade (pharmacies & retail outlets), Modern trade, E-commerce and quick commerce platforms. India’s online beauty and personal care market will also grow rapidly, with 20-25% CAGR (expected).    ]]> https://biospectrumindia.com/news/111/27475/punjab-to-pilot-women-led-community-healthcare-entrepreneurship-programme.html https://biospectrumindia.com/news/111/27475/punjab-to-pilot-women-led-community-healthcare-entrepreneurship-programme.html Thu, 12 Mar 2026 00:00:00 +0530 Punjab has initiated a programme to train and deploy women community health entrepreneurs in villages, to strengthen last-mile healthcare access and support rural livelihoods. Bahaar Foundation has announced the launch of the Sehat Sevika programme in partnership with the Punjab Development Commission (PDC), marking the beginning of an effort to test and refine a community-based healthcare and women’s entrepreneurship model in the state.   The Sehat Sevika Programme commenced in January 2026 with an initial cohort of 100 Sehat Sevikas in Rupnagar district. Insights from this pilot will help shape a phased expansion across other districts in the state in the coming years. To support implementation, Bahaar has embedded a dedicated Project Management Unit (PMU) within the Punjab Development Commission to oversee training, monitoring, and ecosystem coordination. The Indian School of Business (ISB), Mohali, will conduct an independent impact assessment of the initial 100-village pilot to generate evidence and learnings from the pilot. The Sehat Sevika model has already demonstrated measurable impact in states such as Chhattisgarh and Uttar Pradesh. In Bastar district, two batches of Sehat Sevikas (locally referred to as Sangwaris) have, over the last three years, supported a population of approximately 50,000 and established themselves as credible and trusted health and wellness support persons in their communities, while generating supplemental income for their families.   By equipping women with critical knowledge, monetizable skills, networks, and ongoing support systems, the Sehat Sevika programme enables them to generate steady supplemental income while strengthening public health systems. Bahaar Foundation is inviting CSR leaders, philanthropic institutions, healthcare partners, and development agencies to join the Impact Coalition to support the programme’s phased expansion as the model evolves and scales across the state. ]]> https://biospectrumindia.com/news/111/27466/roche-india-partners-with-punjab-govt-to-strengthen-multiple-sclerosis-care.html https://biospectrumindia.com/news/111/27466/roche-india-partners-with-punjab-govt-to-strengthen-multiple-sclerosis-care.html Wed, 11 Mar 2026 00:00:00 +0530 In a landmark step toward strengthening neurological care, the Government of Punjab and Roche Pharma India have launched NeuroSakhi, a first-of-its-kind patient support and awareness initiative. The programme is designed to strengthen care and support systems for women living with Multiple Sclerosis (MS) in the State. The programme aims to strengthen care pathways, awareness and support systems for women navigating this complex neurological condition. The initiative was formalised through a Memorandum of Understanding (MoU) signed between Directorate of Medical Education and Research (DMER), Punjab Govt and Roche Pharma India at the Punjab Civil Secretariat in the esteemed presence of Balbir Singh (Health Minister - Punjab); Kumar Rahul (Principal Secretary – Health); Dr Hitinder Kaur ( Director – Health Services); Dr Rupinder Bakshi (Joint Director – Medical Education & Research) and Dr Dheeraj Khurana (Professor of Neurology, PGIMER Chandigarh).  An expert group led by the Department of Neurology at PGIMER Chandigarh will guide the development of evidence-based treatment pathways and recommendations for early diagnosis and timely treatment initiation. PGIMER Chandigarh will function as the central clinical hub, while Government Medical Colleges in Amritsar, Patiala and Faridkot will serve as regional spokes, enabling coordinated multidisciplinary care for Multiple Sclerosis across the State. The initiative will work toward improving the affordability and accessibility of disease-modifying therapies and high-efficacy treatments through government formulary inclusion and sustainable funding mechanisms. State-wide training programmes will strengthen the ability of physicians to identify MS symptoms early, ensure timely referrals and adopt evidence-based management practices. As part of this effort, PGIMER Neurological Society will support training for Government Medical Colleges serving, through a hub-and-spoke model. ]]> https://biospectrumindia.com/news/111/26807/venus-remedies-inaugurates-132000-sq-ft-state-of-the-art-global-fulfillment-centre.html https://biospectrumindia.com/news/111/26807/venus-remedies-inaugurates-132000-sq-ft-state-of-the-art-global-fulfillment-centre.html Wed, 15 Oct 2025 00:00:00 +0530 Pharmaceutical company Venus Remedies has inaugurated its state-of-the-art Venus Global Fulfillment Centre (VGFC) in Mohali, Punjab. Spanning 132,000 square feet with a built-up area of 66,000 square feet, the facility is designed to significantly enhance the company’s global logistics and supply chain capabilities. Built to meet international standards including WHO GDP, EU GMP, PAHO, CDSCO, GDP AEO, and ISO certifications, the VGFC ensures product integrity, quality compliance, and timely access to medicines across regulated and semi-regulated markets. The centre can process up to 10,000 orders per day across B2B and B2C channels, with current utilisation at approximately 30,000 orders per month. Its infrastructure includes temperature-controlled storage, RFID and barcode-based tracking, and automated sorting and retrieval systems. With capacity for more than 5,000 pallets and storage for over 50 million product units, VGFC is equipped to support dynamic global demand while maintaining precision and reliability. “The VGFC represents a strategic advancement in our global supply framework,” said Saransh Chaudhary, President, Global Critical Care, Venus Remedies Limited, and CEO, Venus Medicine Research Centre. “It enhances our responsiveness to urgent healthcare needs and supports uninterrupted patient access across over 100 countries.”  The facility also aligns with Venus Remedies’ sustainability objectives, integrating energy-efficient HVAC systems, rainwater harvesting, waste management through authorised partners, and eco-conscious logistics practices. With VGFC, Venus Remedies strengthens its ability to serve critical care, oncology, and antimicrobial markets worldwide, supporting the company’s vision to deliver safe, high-quality medicines with operational excellence and global reliability. ]]> https://biospectrumindia.com/news/111/26782/dr-agarwals-eye-hospital-launches-specialised-myopia-clinic-in-chandigarh.html https://biospectrumindia.com/news/111/26782/dr-agarwals-eye-hospital-launches-specialised-myopia-clinic-in-chandigarh.html Wed, 08 Oct 2025 00:00:00 +0530 Dr Agarwals Eye Hospital, one of India’s largest networks of eye care facilities, has launched a specialised Myopia Clinic in Chandigarh to address the alarming rise of near-sightedness among children and young adults. The launch event was done under the aegis of Chandigarh Ophthalmic Society and was graced by doctors from the hospital and was followed by an awareness workshop highlighting early signs of myopia, lifestyle risk factors, and preventive strategies for parents and educators. The clinic offers a holistic approach to managing childhood myopia, including early detection, counselling, education, and regular follow-up care. Equipped with advanced diagnostic technology and a specialised team of paediatric ophthalmologists and optometrists, it provides personalised treatment plans tailored to each child’s needs. It also offers a comprehensive range of myopia-control options from eye drops and specialised glasses to soft contact lenses and orthokeratology (Ortho-K) lenses to effectively manage the condition and minimize potential complications. Dr Rajiv Mirchia, Head Clinical Services – Mirchia’s Laser Eye Center, a unit of  Dr Agarwals Eye Hosptial said, “The launch of our Myopia Clinic in Chandigarh is a significant step towards addressing the growing burden of myopia in Punjab and North India. With childhood cases rising at an alarming pace, our aim is to provide comprehensive care that not only corrects vision but also helps slow the progression of the condition. Through this centre, we want to empower families with awareness, timely intervention, and access to the latest treatment options.” Dr Anin Sethi Senior Pediatric Ophthalmologist said, “Myopia, or near-sightedness, is rising rapidly worldwide, with countries such as China, South Korea, Japan, Singapore, and Taiwan already seeing epidemic levels, affecting up to 95% of teenagers and young adults. By 2050, nearly half of the global population could be myopic. In India, prevalence among urban children aged 5–15 has increased from 4.44% in 1999 to 21.15% in 2019 and is projected to reach 48% by 2050. In Punjab, a 2007 study reported nearly 10% of schoolchildren in urban areas were myopic. Growing academic pressure, reduced outdoor time, and increased screen usage are contributing to higher rates across North India. Beyond clinical care, Dr Agarwals Eye Hospital plans to conduct school-based awareness campaigns and workshops for parents, children, ophthalmologists, and optometrists across Chandigarh and Punjab, reinforcing community-level understanding of myopia prevention. The hospital’s long-term vision is to make myopia management a public health priority. With rising prevalence and increasing severity, the clinic aims to serve as a regional hub for early detection, intervention, and long-term control of childhood myopia. ]]> https://biospectrumindia.com/news/111/26475/government-of-punjab-launches-cancer-care-pathways.html https://biospectrumindia.com/news/111/26475/government-of-punjab-launches-cancer-care-pathways.html Mon, 04 Aug 2025 00:00:00 +0530 The Government of Punjab has launched the Punjab Cancer Care Pathways — a comprehensive initiative introducing Standard Treatment Guidelines (STGs) and streamlined care models for breast, cervical, oral, lung, and liver cancers.The pathways were developed and authored by the expert team from AIIMS Delhi, in collaboration with the Department of Health & Family Welfare, Punjab.The official launch was held in the presence of the Health Minister of Punjab, key contributors, and representatives from the World Health Organization (WHO), ICMR, PGIMER, and other national institutions. This is more than a document — it is a mission to ensure timely detection, evidence-based treatment, and survivor-focused care for the people of Punjab. ]]> https://biospectrumindia.com/news/111/26297/punjab-government-launches-data-intelligence-technical-support-unit-to-strengthen-fight-against-drugs.html https://biospectrumindia.com/news/111/26297/punjab-government-launches-data-intelligence-technical-support-unit-to-strengthen-fight-against-drugs.html Sat, 28 Jun 2025 11:00:00 +0530 In a decisive step towards combating drug and substance abuse, the Government of Punjab has launched the Data Intelligence and Technical Support Unit (DITSU) - a pioneering initiative under its flagship campaign Yudh Nasheyan Virudh (War Against Drugs). This first-of-its-kind public-private collaboration is supported by the Ananya Birla Foundation (ABF) and is poised to drive systemic, data-driven reforms to create a drug-free Punjab. The launch was formalised through the signing of a Memorandum of Understanding between Bhagwant Mann, Chief Minister of Punjab and Ananya Birla, Founder of ABF.  DITSU will serve as the state's central technical and data insights hub, enabling the development of evidence-based policies, strategic interventions, and improved coordination across enforcement agencies, healthcare systems, and community-based organisations. The unit will be headquartered at the Dr. B.R. Ambedkar State Institute of Medical Sciences, Mohali. As part of the collaboration, the Ananya Birla Foundation will provide strategic support for hiring of key personnel, including the co-development of a digital platform for real-time tracking of Drugs of Concern (DoC). This will significantly strengthen monitoring and timely response capabilities across districts. The partnership is designed to drive impact across several key areas which include capacity building through training and up-skilling of psychologists, counsellors, peer educators, and frontline health workers; launching evidence-based prevention programmes and awareness campaigns in schools and colleges; and facilitating seamless collaboration between state departments, academic institutions, and law enforcement.   ]]> https://biospectrumindia.com/news/111/26258/scientists-in-mohali-design-method-to-synthesise-nano-cups-that-can-blaze-cancer-with-heat.html https://biospectrumindia.com/news/111/26258/scientists-in-mohali-design-method-to-synthesise-nano-cups-that-can-blaze-cancer-with-heat.html Tue, 17 Jun 2025 00:00:00 +0530 Scientists from the Institute of Nano Science and Technology (INST), Mohali, an autonomous institute under the Department of Science and Technology (DST), in collaboration with researchers from Advanced Centre for Treatment Research & Education in Cancer, Tata Memorial Centre (ACTREC) and Indian Institute of Technology, Bombay (IIT-B), have developed a novel one-step colloidal synthesis method for fabricating PEGylated semi-shells (SS) with nano-cup morphology at room temperature. The novel one-step colloidal synthesis method for nanoparticles with a unique shell structure with nano-cup morphology that is partly covered with polyethylene glycol (PEG) can help with photothermal therapy (PTT) to treat cancer. The simplified yet highly unique approach circumvents all the drawbacks of previously reported processes by using a biocompatible metal-organic framework (MOF), ZIF-8, as a sacrificial template. The synthesis employs mild reducing agents like ascorbic acid (Vitamin C) at room temperature. Future studies aim to explore chemo-photothermal therapy for highly selective oncological applications and investigate the potential of these semi shells in Surface-Enhanced Raman Spectroscopy (SERS) biosensing, leveraging their unique optical properties for advanced biomedical applications. ]]> https://biospectrumindia.com/news/111/26234/lpu-launches-healthcare-courses-for-child-and-elder-care.html https://biospectrumindia.com/news/111/26234/lpu-launches-healthcare-courses-for-child-and-elder-care.html Thu, 12 Jun 2025 00:00:00 +0530 Lovely Professional University (LPU), in Punjab, has launched India’s most future-forward healthcare programmes- B.Sc. and Diploma courses in Child and Elderly Care; marking a significant milestone in Allied Health Sciences education. As the world faces an unprecedented surge in demand for skilled caregivers, LPU’s pioneering initiative opens up exceptional global career pathways for students. These programmes are more than just academic offerings; they are life-changing opportunities to become part of one of the fastest-growing professions across countries like Canada, Australia, the UK, and the US. With limited seats and soaring interest, missing this wave now could mean missing out on a future-proof career in global healthcare. The newly launched programmes, available as a 2-year Diploma and a 3-year B.Sc. degree, are tailored to address critical workforce shortages in child and elderly care; two of the most rapidly growing healthcare domains worldwide. These programmes equip students with hands-on competencies in caregiving, health and wellness management, psychosocial support, and safety protocols for vulnerable age groups such as infants, children, and the elderly. The curriculum is aligned with international caregiving standards, ensuring that graduates are ready for direct placement in countries where the demand for professional caregivers is surging due to aging populations and evolving family structures. From Geriatric Care Assistants and Home Care Coordinators to careers in Palliative Care, Elderly Wellness Coaching, and even entrepreneurial roles like running day care centres or senior living homes; students are positioned to enter high-impact, high-respect professions. Opportunities also exist in hospitals, rehabilitation centres, NGOs, private care agencies, and global caregiving networks.   ]]> https://biospectrumindia.com/views/111/25895/its-important-for-healthcare-startups-in-india-to-recognise-the-price-sensitiveness-of-the-market.html https://biospectrumindia.com/views/111/25895/its-important-for-healthcare-startups-in-india-to-recognise-the-price-sensitiveness-of-the-market.html Mon, 31 Mar 2025 00:00:00 +0530 Could you share some of 2024’s most impactful milestones for RNT Health Insights and key plans for 2025? During 2024, RNT Health Insights achieved significant milestones, including receiving the US FDA Breakthrough Device Designation for two of our Medical Devices- one intended for Early Gastric Cancer detection and the other for detecting Early-stage Oesophageal Cancer. Oesophageal cancer is the fourth leading cause of cancer-related deaths in India and the sixth leading cause of cancer-related deaths worldwide, claiming over 540,000 lives annually. Its prognosis is notably poor, with a five-year survival rate of less than 20 per cent. This is primarily due to the associated high miss rate of detection during early stages and attributed to the fact that it is almost always detected at an advanced stage.  Likewise, despite gastrointestinal endoscopic procedures being the gold standard method for the diagnosis of gastric cancer, the current miss rate for the diagnosis of the disease during these procedures stands at 4.6-25.8 per cent, depending upon the endoscopists’ experience and visual observations. Recently, we have also secured the Central Drugs Standard Control Organisation (CDSCO) Test License in India, and were honoured with prestigious non-dilutive grants including the WTFund grant, as well as the Pfizer INDovation NIPER-A edition programme grant, conducted by Pfizer, Social Alpha, Department of Pharmaceuticals, and NITI Aayog and also a Research and Development grant from Emergent Ventures- Mercatus Center at George Mason University, USA. In 2025, we are focused on obtaining the necessary regulatory approvals and then commercialising our breakthrough medical devices in India, aiming to transform gastrointestinal diagnostics across all endoscopy suites nationwide. How does the technology behind your AI-assisted detection tool improve real-time diagnostic precision?  The technology behind our artificial intelligence (AI)-assisted detection tool integrates advanced spatial and temporal computer vision algorithms. This allows for the meticulous analysis of every single video frame in real time, detecting subtle lesions while also understanding the dynamic relationships of various parameters over time. Our models are designed for optimal latency, processing data and delivering predictions within 25 milliseconds per frame to ensure smooth integration into existing endoscopy workflows. This unique combination of high accuracy and swift processing, along with a robust learning framework trained on a diverse and heterogenous dataset of cancerous as well as non-cancerous lesions, positions our medical devices as an essential tool in enhancing diagnostic accuracy during endoscopic procedures. Are there any upcoming product launches or partnerships in the pipeline? Our Automated Endoscopy Report Generation software was launched in February 2025. It is a tool designed to streamline and automate the labour-intensive manual reporting workflows in endoscopy suites. Our Automated Endoscopy Report Generation software, ReportGI, is available to use from March 15 onwards. Additionally, we are preparing for the launch of our esophageal and gastric cancer detection medical devices in India, after obtaining the CDSCO Manufacturing License and other necessary regulatory approvals, in the latter half of the year. This launch will be in collaboration with our pilot research hospital centres. We are also exploring opportunities to expand our product portfolio both horizontally and vertically, developing new algorithms in close collaboration with key opinion leaders in the field. What are the key regulatory and market challenges you face in bringing AI-based diagnostic tools to broader markets? Navigating the evolving landscape of regulatory standards for AI-driven Medical Devices presents significant challenges due to the nascent nature of this technology in healthcare. Our commitment to transparency and adherence to rigorous safety and efficacy standards are fundamental as we build our startup. Additionally, fostering stakeholder engagement, driving adoption, and aligning our developments with clinical practices and workflows are pivotal to our strategy, despite the inherent challenges in introducing novel diagnostic tools in the Indian healthcare market. What are the current challenges and trends facing the medtech/ diagnostic startups in India? The evolving landscape of medtech and diagnostic startups in India is characterised by a shift away from a one-size-fits-all approach in patient care towards personalised medicine. This is driven by the capability to analyse and interpret healthcare data with high accuracy and then provide actionable insights. Personalised diagnostics and the use of sophisticated algorithms, such as deep learning, are emerging as key trends and are shaping the future of healthcare technology. The primary challenges faced by startups in this sector include navigating the complex regulatory landscape, which is continuously adapting to such new technologies, and meeting the stringent requirements for clinical validation necessary to gain acceptance within the medical community. To make a mark for themselves in the medtech sector, do Indian startups prefer getting global approvals first and then launching their products in India? Is there a trend, or are there challenges surrounding approvals in India for medtech startups? Or are there any quality constraints? Indian medtech startups are increasingly focusing on capturing the domestic market before scaling globally, supported by the government's push for self-reliance in medical device manufacturing. Indian doctors have the finest training in the world and are adept at adopting and utilising new technology. However, a large portion of the cost of new medical technology is borne by the patients- and healthcare startups in India need to recognise the price sensitiveness of the Indian market. To build for the Indian medtech industry, and making a significant difference to the quality of Indian healthcare and then expanding globally is a fulfilling path, that startups like ours intend to undertake, and with initiatives like the Meditech Mitra scheme, the process of obtaining regulatory approvals in India has become more scientific and transparent and supportive for startups. How has funding accelerated your growth, and are there any recent investments you’d like to highlight? Our growth has been substantially accelerated by funding and support from organisations such as IKP Eden, WTFund, Social Alpha and Pfizer, Emergent Ventures, and the Department of Science and Technology (DST), Government of India. These partnerships have not only provided financial backing through grants and funding support but have also facilitated essential hospital and research collaborations, helped us expand our technical team, and supported our progress towards critical regulatory milestones, allowing us to broaden our scope of operations and impact within the healthcare sector.   Vrushti Kothari (vrushti.kothari@mmactiv.com) ]]> https://biospectrumindia.com/news/111/25693/jujhar-group-partners-with-apollo-hospitals-to-establish-super-speciality-hospital-in-mohali.html https://biospectrumindia.com/news/111/25693/jujhar-group-partners-with-apollo-hospitals-to-establish-super-speciality-hospital-in-mohali.html Tue, 18 Feb 2025 00:00:00 +0530 In a significant step toward strengthening healthcare infrastructure in North India, Punjab-based Jujhar Group has announced a strategic collaboration with Apollo Hospitals Enterprise Limited (AHEL). This partnership will pave the way for the establishment of a cutting-edge 625+ bedded super-speciality hospital, designed to deliver world-class medical services and redefine healthcare standards in the region. The upcoming facility will provide a wide spectrum of super-speciality services, including cardiology, oncology, orthopaedics, neurology, and gastroenterology, ensuring comprehensive care under one roof. By integrating advanced medical technology, exceptionally skilled professionals, and world-class infrastructure, the hospital aims to set a new benchmark in patient care, focusing on both clinical excellence and compassionate treatment. The agreement was formally signed by Arshdeep Singh, Executive Director of Jujhar Group, alongside Dr Prathap C Reddy, Chairman of AHEL, and Suneeta Reddy, Managing Director of AHEL. This collaboration combines Apollo Hospitals’ extensive expertise across the healthcare ecosystem including hospitals, pharmacies, primary care, and diagnostic clinics; with the Jujhar Group’s robust regional presence and infrastructure capabilities. The hospital’s strategic proximity to Chandigarh International Airport positions it as a premier hub for International Medical Value Travel, offering advanced treatment options and holistic care to global patients.  Spanning 6.17 acres with a built-up area exceeding 12 lakh square feet, the hospital's well-connected location provides effortless access to patients across Punjab, Himachal Pradesh, Haryana, and the Union Territory of Chandigarh, offering a transformative healthcare solution for the region. ]]> https://biospectrumindia.com/news/111/25680/fortis-to-acquire-228-bedded-shrimann-superspecialty-hospital-in-jalandhar-for-rs-462-cr.html https://biospectrumindia.com/news/111/25680/fortis-to-acquire-228-bedded-shrimann-superspecialty-hospital-in-jalandhar-for-rs-462-cr.html Sat, 15 Feb 2025 00:00:00 +0530 Fortis Healthcare Limited (FHL) has signed definitive agreements for the acquisition of Shrimann Superspecialty Hospital in Jalandhar, Punjab from inter alia Shriman Enterprises (a partnership firm) by way of a slump sale. The acquisition would be undertaken by Fortis' wholly-owned subsidiary Fortis Hospotel Limited (FHTL) and is subject to FHL shareholder approval. As part of the transaction, FHTL would acquire the entire business operations, hospital building of Shrimann Hospital, as well as the underlying hospital land. In addition, an adjunct land parcel for possible future expansion is also being acquired. The transaction will be an all-cash deal for an overall purchase consideration of approx. Rs 462 crore (excluding stamp duty and other regulatory costs) and shall be subject to customary closing adjustments as agreed in the definitive agreements.   The acquisition is in line with the company’s cluster-focused inorganic growth strategy and further bolsters Fortis’ network in the state of Punjab. Shrimann Hospital, Jalandhar adds to the company’s existing presence in the key cities of Punjab including Mohali, Amritsar and Ludhiana. The acquisition will enable the company to scale up and further deliver quality healthcare services to patients in Jalandhar as well as in surrounding catchment areas. Shrimann Hospital, is amongst the leading multi-specialty hospitals in Jalandhar, commissioned in 2018. The facility is NABH accredited and offers a complete range of super specialties including the key specialties such as Cardiac Sciences, Nephrology, General and Laparoscopic Surgery, Oncology, Neuro Sciences and Gastroenterology. For FY 2024-25 (basis annualized 9-month FY numbers) the hospital is expected to generate revenues of ~Rs 154 crore with an EBITDA of ~Rs 36 crore. The transaction is estimated to be consummated by end of March 2025, subject to the completion of certain customary conditions precedent as stipulated in the definitive agreements.   ]]> https://biospectrumindia.com/news/111/25627/scientists-in-mohali-design-drug-delivery-system-to-revolutionise-treatment-of-rheumatoid-arthritis.html https://biospectrumindia.com/news/111/25627/scientists-in-mohali-design-drug-delivery-system-to-revolutionise-treatment-of-rheumatoid-arthritis.html Tue, 04 Feb 2025 00:00:00 +0530 Researchers from Institute of Nano Science and Technology (INST) Mohali, an autonomous institution of the Department of Science and Technology (DST), have developed an innovative “self-actuating” drug delivery system that could revolutionise the treatment of rheumatoid arthritis (RA) by targeting inflammation directly within the joints so that therapeutic agents are released only when needed. It is a smart system that responds directly to the biochemical signals in the inflamed synovial environment. By targeting specific inflammatory enzymes present in the joints, the system ensures that therapeutic agents are released only when needed, offering a more precise and safer treatment option for RA patients. This breakthrough could offer a safer, more effective alternative to current RA treatments by eliminating the need for frequent drug injections and reducing systemic toxicity. The system enhances drug effectiveness by improving bioavailability and retention in the affected joints, leading to longer-lasting relief with fewer doses.  Beyond arthritis, the technology holds promise for managing other inflammatory diseases, such as synovitis and inflammatory bowel disease. It could also pave the way for smart biomaterials in regenerative medicine and personalised treatments. Additionally, its potential use in veterinary medicine for managing arthritis in animals highlights its versatility. ]]> https://biospectrumindia.com/news/111/25478/scientists-in-mohali-identify-nano-plastics-as-emerging-agents-in-spread-of-antibiotic-resistance.html https://biospectrumindia.com/news/111/25478/scientists-in-mohali-identify-nano-plastics-as-emerging-agents-in-spread-of-antibiotic-resistance.html Fri, 20 Dec 2024 00:00:00 +0530 Nanoplastics derived from single-use plastic bottles (SUPBs) contribute to the spread of antibiotic resistance (AR), shows a new study, underscoring an unrecognised public health risk. Scientists from Institute of Nano Science and Technology (INST) Mohali, an autonomous institution of the Department of Science and Technology (DST), traced how plastic nanoparticles could impact bacteria. Recognising the central role of Lactobacillus acidophilus in the gut microbiota, Dr Manish Singh and his team investigated whether nano-plastics could transform beneficial bacteria into carriers of AR genes and pose a risk to human gut microbiome health. They utilised the used plastic water bottles to synthesise environmentally relevant nanoplastics particles as these polyethylene terephthalate bottle-derived nanoplastics (PBNPs) better represent the actual pollutant nanoplastics generated due to dumping of single use plastic bottles and containers. The scientists demonstrated that PBNPs can facilitate the cross-species gene transfer from E. coli to Lactobacillus acidophilus, a significant bacteria found in human gut microbiota, through a process called horizontal gene transfer (HGT), particularly through outer membrane vesicle (OMV) secretion in bacteria. Protecting beneficial gut bacteria is crucial for immune support, digestion, and disease prevention. Limiting nanoplastic contamination could help preserve gut microbiota integrity, minimising the chances of AR gene transfer from beneficial to pathogenic bacteria and supporting microbiome resilience. With increasing plastic pollution, this finding highlights the need for strict safety guidelines, awareness programmes as well as the necessity of policies that prioritise responsible usage of plastics and it’s adequate waste management to safeguard the human health and microbiome stability. ]]> https://biospectrumindia.com/news/111/25470/iit-ropar-inaugurates-tinkerers-lab-for-advancements-in-stem-education.html https://biospectrumindia.com/news/111/25470/iit-ropar-inaugurates-tinkerers-lab-for-advancements-in-stem-education.html Tue, 17 Dec 2024 00:00:00 +0530 The Indian Institute of Technology (IIT) Ropar has announced the opening of its new Dr Ranbir Singh Tinkerers' Lab (TL), a cutting-edge facility designed to inspire and nurture the next generation of engineers and innovators. This maker space is accessible to all students around the clock and has been made possible by funding from the Maker Bhavan Foundation (MBF) through a donation from philanthropist Dr Ranbir Singh.                                                                        The inauguration ceremony took place on campus and was attended by faculty, students, and guests. This event marks a significant step forward in the field of Science, Technology, Engineering, and Mathematics (STEM) education at IIT Ropar.  Dr Ranbir Singh Tinkerers’ Lab is more than just a workspace; it is a creative hub for aspiring engineers, innovators, and makers. The lab encourages students to view technology not just as a subject in school but as a powerful tool for creativity and future focused skilling for young engineers. The environment is designed to empower students to explore and experiment, allowing them to tinker, build, and innovate their ideas into real-world products.      The lab is equipped with state-of-the-art tools and technology. Students will have the chance to experiment and work on their projects any time of the day. This open access will help them freely explore their ideas beyond standard academic hours, leading to original and innovative projects.          ]]> https://biospectrumindia.com/news/111/25338/iit-ropar-designs-patented-mechanical-knee-rehab-device.html https://biospectrumindia.com/news/111/25338/iit-ropar-designs-patented-mechanical-knee-rehab-device.html Mon, 11 Nov 2024 00:00:00 +0530 In a significant breakthrough for post-surgical knee rehabilitation, researchers at the Indian Institute of Technology (IIT) Ropar have unveiled an innovative solution to make continuous passive motion (CPM) therapy more accessible and affordable. The team at IIT Ropar has developed a Completely Mechanical Passive Motion Machine for Knee Rehabilitation that has been awarded a patent. Unlike traditional motorised CPM machines, which are expensive and depend on electricity, the newly developed device is entirely mechanical. It utilises a piston and pulley system, which stores air as the user pulls a handle, enabling smooth and controlled motion to aid in knee rehabilitation. This simple yet effective design eliminates the need for electricity, batteries, or motors, making it both lightweight and portable. The mechanical CPM machine offers a promising alternative to costly electric machines that are often out of reach for many patients, especially in rural areas with unreliable electricity supply. By reducing the reliance on electricity, it makes continuous passive motion therapy feasible even in off-grid locations. Additionally, its portability allows for patients to use it in the comfort of their homes, reducing the need for prolonged hospital stays and rehabilitation visits. “This device has the potential to revolutionise knee rehabilitation in India, where access to advanced medical technology can be limited, particularly in rural areas,” said Dr Abhishek Tiwari, the lead researcher, along with his team comprising Suraj Bhan Mundotiya and Dr Samir C. Roy. “It’s designed to be a low-cost, sustainable solution that not only aids in recovery but also helps reduce the environmental impact associated with motorised devices”, he added. ]]> https://biospectrumindia.com/news/111/25301/health-minister-dr-balbir-singh-unveils-stroke-care-model-in-partnership-with-cmc-ludhiana-and-medtronic.html https://biospectrumindia.com/news/111/25301/health-minister-dr-balbir-singh-unveils-stroke-care-model-in-partnership-with-cmc-ludhiana-and-medtronic.html Tue, 29 Oct 2024 00:00:00 +0530 Punjab Health Minister Dr Balbir Singh has announced a transformative collaboration between the Government of Punjab, Christian Medical College (CMC) Ludhiana, and India Medtronic Private Limited. This first-of-its-kind public-private partnership in India aims to combat the rising burden of stroke in Punjab by creating a streamlined stroke care pathway for timely and effective treatment. Dr Balbir Singh said, "The collaboration between the Government of Punjab, CMC Ludhiana, and Medtronic marks a significant milestone in healthcare innovation. With a clear focus on improving access to critical care, this initiative aims to reduce stroke-related deaths and disabilities, setting a new standard for stroke management in India." The partnership introduces a Hub and Spoke model for stroke care, designed to improve patient outcomes by providing rapid, coordinated care. CMC Ludhiana, a leading Medical Institution and India’s first Advanced Stroke Center certified by the World Stroke Organization and NABH, will serve as the central "Hub" for advanced Stroke treatment. A network of Government Hospitals and Medical Colleges across the state will act as "Spoke" centres, responsible for providing immediate care and stabilising stroke patients before referring them to the hub for advanced interventions like mechanical thrombectomy. ]]> https://biospectrumindia.com/news/111/25013/plaksha-university-opens-anthem-biosciences-natures-machines-lab-in-mohali.html https://biospectrumindia.com/news/111/25013/plaksha-university-opens-anthem-biosciences-natures-machines-lab-in-mohali.html Fri, 09 Aug 2024 00:00:00 +0530 Plaksha University has announced the inauguration of the Anthem BioSciences Nature’s Machines Lab, a pathbreaking facility dedicated to fostering experiential learning and interdisciplinary research in biosciences. This lab, sponsored by Anthem BioSciences, is all set to make a significant impact on over 1,500 students in the next five years. Part of the Havells Research Building at the Mohali campus, the Nature’s Machines Lab spans approximately 1,500 square feet and is designed to connect students with the intricate machinery of the natural world. The lab aims to promote ecological awareness and the application of biological concepts through modern tools, advanced research techniques, and interdisciplinary thinking. This research lab is a hub for engaging neighboring communities, high school educators, and other stakeholders in developing biological literacy and stewardship. Nature’s Machines Lab will be equipped for following training and research activities: Cell biology: Students will learn basic and advanced microscopic techniques that will allow them to study cells and their behavior. Nanobiology: Students will learn to isolate, express-purify and analyse biomolecules – molecular machines – from various sources, which will enable them to study, characterize and understand the biological world at the nano scale. Genetic Engineering: Students will learn to edit genes in bacteria and insect cells using conventional and CRISPR based techniques enabling them to design and produce cells with novel functionalities. Environmental Monitoring: Students will analyse water and soil samples to assess environmental health, detect pollutants and develop measures to mitigate environmental risks at local and global level. UG Research Projects: Students can innovate and engineer interdisciplinary solutions for challenges related to human and planetary health through their internship and capstone projects.   ]]> https://biospectrumindia.com/news/111/24260/researchers-in-punjab-develop-new-prototype-to-generate-neurovascular-organoids-from-autologous-blood.html https://biospectrumindia.com/news/111/24260/researchers-in-punjab-develop-new-prototype-to-generate-neurovascular-organoids-from-autologous-blood.html Mon, 26 Feb 2024 00:00:00 +0530 Researchers of Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh have come up with a prototype for establishment and characterisation of novel self-organising neurovascular organoids/ embryoids (NVOEs) entirely from autologous blood without any genetic maneuvering or morphogen supplementation. This new model for generating mass of neurovascular tissues or neurovascular organoids/embryoids (NVOEs) from autologous blood can help in the investigation of impaired brain functioning and development by analysing in neuroimaging (preclinical) scans, correlating with altered blood supply. The field of neural organoids is rapidly progressing and has fueled the hope (and hype) for improved understanding of brain development and functions, modeling of neural diseases, discovery of new drugs, and supply of surrogate sources of transplantation.  The researchers who are in the process of filing a patent for this at the Punjab State Council for Science and Technology, Chandigarh, are employing these models to understand the genetic basis of neurosensory hearing loss and auditory comprehension challenges (altered central auditory activity) in children with congenital Sensorineural Hearing Loss (SNHL) (early onset), with and without comorbid features (autistic- like behaviour) or neurodevelopmental defects (intellectual disability, language disorders).  ]]>